Research Analysts’ Recent Ratings Updates for OptimizeRx (OPRX)

OptimizeRx (NASDAQ: OPRX) has recently received a number of price target changes and ratings updates:

• 4/16/2024 – OptimizeRx had its “market outperform” rating reaffirmed by analysts at JMP Securities. They now have a $15.00 price target on the stock.
• 4/4/2024 – OptimizeRx is now covered by analysts at JMP Securities. They set a “mkt outperform” rating and a $15.00 price target on the stock.
• 4/1/2024 – OptimizeRx had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $17.00 price target on the stock.
• 4/1/2024 – OptimizeRx had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $13.00 price target on the stock.

OptimizeRx Stock Down 3.5 %

Shares of OptimizeRx stock opened at $9.96 on Wednesday. OptimizeRx Co. has a 52-week low of $6.92 and a 52-week high of $16.65. The firm’s 50 day moving average price is $13.59 and its 200-day moving average price is $11.98. The company has a market cap of $180.77 million, a P/E ratio of -12.45 and a beta of 0.98.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Kennedy Capital Management LLC acquired a new position in OptimizeRx in the 3rd quarter worth approximately $4,323,000. Jacob Asset Management of New York LLC raised its stake in shares of OptimizeRx by 30.1% during the 3rd quarter. Jacob Asset Management of New York LLC now owns 370,330 shares of the company’s stock valued at $2,881,000 after buying an additional 85,720 shares during the last quarter. Quadrature Capital Ltd acquired a new position in shares of OptimizeRx in the 3rd quarter valued at about $162,000. Tower Research Capital LLC TRC boosted its stake in shares of OptimizeRx by 407.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,765 shares of the company’s stock worth $97,000 after buying an additional 5,432 shares during the last quarter. Finally, Quantbot Technologies LP purchased a new stake in shares of OptimizeRx in the third quarter worth about $49,000. 76.47% of the stock is owned by institutional investors and hedge funds.

OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers (HCPs), and patients. Its products and applications include Evidence-Based Physician Engagement solution to assist HCPs in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations; and Point of Care Banner messaging solution to deliver a variety of awareness and messaging within the clinical workflow.